PRECLINICAL RESULTS WITH A NOVEL INTERNALLY LOADED DRUG-FILLED CORONARY STENT  by Stone, Gregg et al.
TCT@ACC-i2: Interventional Cardiology
A1762
JACC March 17, 2015
Volume 65, Issue 10S
preCliniCal resUlts with a novel internally loaded drUG-Filled Coronary stent
Poster Contributions
Poster Hall B1
Saturday, March 14, 2015, 3:45 p.m.-4:30 p.m.
Session Title: Coronary II
Abstract Category: 34. TCT@ACC-i2: Coronary Intervention: Devices
Presentation Number: 2101-275
Authors: Gregg Stone, Ajay Kirtane, Alexandre Abizaid, Stephen Worthley, Stefan Tunev, Daniel Schulz-Jander, Robert Melder, Columbia 
University Medical Center / New York-Presbyterian Hospital, New York, NY, USA
background:  A non-polymeric drug-eluting stent (DES) offers theoretical safety and efficacy advantages. However, controlled drug release 
in the absence of a polymer carrier vehicle has proven challenging.
methods:  The internally loaded drug-filled stent (DFS, Medtronic, Santa Rosa, CA) has a hollow lumen containing sirolimus (1.1 ug/mm2) 
and laser cut abluminal fenestrations (average 5/strut, average minimal bore diameter 20 um) for controlled drug release. 559 DFS were 
implanted in porcine coronary pharmacokinetic and histology studies to evaluate the performance of this device.
results:  67.5% ± 6.9% and 93.2% ± 2.1% of drug were released at 28 days and 90 days, respectively (Figure left). In vivo tissue drug 
levels peaked at 1.6 ± 0.5 ng/mg at 24 hours and remained ≥0.5 ng/mg through 90 days (Figure right). Histology demonstrated effective 
suppression of neointimal hyperplasia at 28 days (diameter stenosis 13.2% ± 3.4% vs. 21.0% ± 7.5% with BMS, P<0.0001). Fibrin scores 
demonstrated drug effect through 90 days, then fell to control levels. Inflammation was minimal at all time periods.
Conclusion:  The internally loaded DFS is a unique DES platform which provides therapeutic sirolimus delivery to the arterial wall in the 
absence of a polymer carrier. On the basis of these data, the first-in-human clinical trial with DFS is projected to begin in mid-2015.
 
